10 Av. Princesse Grace
Abviris Deutschland GmbH will be exhibiting at EUROGIN, an international congress on HPV-related disease, which takes place in Monaco on December 4-7. You can find our stall (#D08) in the exhibition area in the Grimaldi forum, opposite of the lecture theatre POULENC CONFERENCE. We are looking forward to talking to scientists, clinicians and commercial partners wishing to join our mission to improve patient outcomes in oncology.
Our product Prevo-Check®, a patented test for the detection of HPV16-induced tumours, is the focus of two studies to be presented at this year’s EUROGIN congress.
In a study conducted at the University of Graz, Dr. Weiland and colleagues discovered that Prevo-Check® is a rapid test for identifying patients with HPV16-induced oropharynx carcinoma, with a sensitivity of 95%. Furthermore, the tumour marker DRH1 could be used to monitor patient outcomes during and after cancer treatment. To learn more, see abstract #0669: “DRH1 – Evaluating a blood-based marker for HPV16-induced tumors” and visit the poster during the poster session.
A further study conducted by Dr. Skaletz-Rorowski and Prof. Dr. med. Brockmeyer from the Center for Sexual Health at the University of Bochum evaluated the use of Prevo-Check® in the early detection of anal carcinoma in patients with HIV. This evidence will be presented as part of the session ‘Free Communications/Anal Neoplasia’, scheduled for Friday 6 December 10:00–11:30. To learn more, see abstract #0366: “A blood-based tumor marker for the early detection and monitoring of HPV-induced anal cancer in HIV-patients”.